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Objective: To evaluate the scientiﬁc basis for the use of Kang 601 heji (K-601) as an
anti-inﬂammatory and antipyretic agent using appropriate animal models.
Methods: Carrageenan-induced rat paw and xylene-induced ear oedemas were models
used to investigate anti-inﬂammatory actions of K-601. Lipopolysaccharide-induced
pyrexia model was used to evaluate antipyretic activity in Wistar rats. The anti-
inﬂammatory and antipyretic mechanisms were evaluated by detecting prostaglandins
E2, nitric oxide, interleukin-1b and tumour necrosis factor-a levels using appropriate
reagents and ELISA kits.
Results: The results revealed that K-601 reduced the level of inﬂammations in both anti-
inﬂammatory models in a dose-dependent manner. The same was true for the antipyretic
model. The possible mechanisms of actions were through the inhibition of prostaglandins
E2, interleukin-1b, tumour necrosis factor-a and nitric oxide.
Conclusions: K-601 has proven anti-inﬂammatory and antipyretic actions. The ﬁndings
provide a scientiﬁc basis for the use of K-601 as anti-inﬂammatory and antipyretic agent
in traditional Chinese medicinal practice.1. Introduction
Inﬂammation is deﬁned as the biological response of the body
to local injury and infection, characterized by redness, oedema,
fever, pain, and loss of function. It involves a cascade of events
elicited by numerous stimuli that include infectious agents,
ischaemia, thermal and physical injury, and antigen–antibody
interaction [1]. Even though inﬂammation is the defence
mechanism of the body to eliminate or limit the spread of
injurious stimuli and heal the wounds, excessive inﬂammationis associated with onset of diseases like rheumatoid arthritis,
asthma, periodontitis, inﬂammatory bowel disease,
atherosclerosis, Alzheimer's disease and even cancer such as
gall bladder carcinoma [2]. Non-steroidal anti-inﬂammatory
drugs are widely used in the treatment of acute and chronic
inﬂammation, pain, and fever. Their use is associated with
adverse effects like severe gastritis, peptic ulcer, nausea, vomit-
ing, salt and water retention, worsening of renal function in renal
or cardiac and cirrhotic patients, hypersensitivity, etc. [3].
Therefore, there is a need for screening and development of
anti-inﬂammatory drugs which are devoid of these unwanted
effects. As herbal medicines lack these side effects, the current
trend is to conduct investigations on plant-based drugs. Accord-
ing to the World Health Organization, about 80% of the world
population still relies mainly on traditional herbal remedies [4].
Fever is the regulated rise in body temperature above the
normal range which is usually considered as a sign of an
infection. Though a defence mechanism, sustained fever hasan open access article under the CC BY-NC-ND
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vulsions, cardiopulmonary strain, localized lesions and other
teratological consequences [5]. The most common cause of fever
is bacterial infections, and mimicked experimentally by the
systemic injection of lipopolysaccharide (LPS). LPS is a major
component of Gram-negative bacterial cell wall. The induction
of fever involves an array of cytokines [interleukin-1b (IL-1b),
interleukin-6 (IL-6), tumour necrosis factor-a (TNF-a), etc.] and
other mediators leading to the production of cyclooxygenase-2-
dependent prostaglandin E2 (PGE2) [6].
Kang 601 heji (K-601) is a traditional Chinese remedy for
common cold comprising ﬁve herbs, Lonicera japonica Thunb.
(L. japonica), Isatis indigotica Fort. (I. indigotica), Rheum
palmatum L., Phellodendron chinense Schneid. (P. chinense),
and Scutellaria baicalensis Georgi (S. baicalensis). It is usually
used due to its ability to alleviate the symptoms of common cold
such as headache, fever, inﬂammation and general bodily pain,
etc. Though data from scientiﬁc literature provide information
on individual herbs in the formulation, there is no scientiﬁc
evidence available of this unique formulation to justify its use.
The aim of this work was to investigate the anti-inﬂammatory
and antipyretic properties of this formulation using appropriate
animal models. This work also aimed at identifying the chemical
make-up of this formulation which could help explain its
possible mechanisms of action.2. Materials and methods
2.1. Drug formulation, chemicals and reagents
K-601 was purchased from Nanjing Children Hospital
Indomethacin (Shaanxi Yuupeng Pharm. Co. Ltd) and dexa-
methasone (Jinan Limin Pharmaceutical Co., Ltd.) were used in
this study. Sterile normal saline solution was purchased from
Anhui Shuanghe Pharmaceutical Co., Ltd. LPS (Escherichia coli
055:B5) was purchased from Sigma–Aldrich. Carrageenan was
bought from Aladdin Chemistry Co. Ltd. High performance
liquid chromatography grade acetonitrile was purchased from
Merck (Darmstadt, Germany). Distilled water was puriﬁed by
Milli-Q system (Millipore, USA). High performance liquid
chromatography grade methanol was gotten from Jiangsu Han-
bon Sci. & Tech. Co. Ltd. (Jiangsu, China). Analytical grade
formic acid was purchased from Nanjing Chemical Factory
(Nanjing, China). Kits for ELISA were purchased from Cusabio
Biotech., Co., Ltd. (Wuhan, China).
2.2. Identiﬁcation of chemical constituents of K-601
About 1 mL of K-601 was dissolved in 1 mL of distilled
water. The resultant solution was centrifuged at 13000 r/min for
10 min and the supernatant was transferred to a sample vial for
ultra performance liquid chromatography-mass spectrometer
(UPLC-MS) analysis.
Chromatographic analysis was performed on an Agilent 1290
Series (Agilent Corp., Santa Clara, CA, USA). UPLC system
equipped with a binary pump, micro degasser, an auto sampler
and a thermostatically controlled column compartment. Chro-
matographic separation was carried out at 25 C on a Zorbax
RRHD eclipse plus C18 column (2.1 mm × 50 mm, 1.8 mm). The
mobile phase consisted of 0.1% formic acid solution (A) and
acetonitrile (B) using a gradient elution of 0%–5% B at 0–6 min,5%–8% B at 6–15 min, 8%–15% B at 15–20 min, 15%–20% B
at 20–30 min, 20%–30% at 30–35 min, 30%–35% at 35–45 min,
35%–40% at 45–60 min. The ﬂow rate was kept at 0.2 mL/min,
and the sample volume injected was set at 5 mL. Detections were
carried out by Agilent 6530 Q/TOF mass spectrometer (Agilent
Corp., Santa Clara, CA, USA) equipped with an electrospray
ionization interface. The parameters of operation were as fol-
lows: drying gas N2 ﬂow rate, 10.0 L/min; temperature, 330 C;
nebulizer, 35 psig; capillary, 3000 V; skimmer, 60 V; Oct RFV,
250 V. Each sample was analyzed in both the positive and
negative modes due to the selective sensitivities to different
components of the formulation-providing better information for
molecular formulae and structural identiﬁcation. Mass spectra
were recorded across the range m/z 100–1000 with accurate
mass measurements.
2.3. Animals
Male Wistar albino rats from Yangzhou University Cooper-
ative Medicine Center weighing 180–220 g were used for the
study. They were housed in acryl ﬁbre cages at (24 ± 2) C,
humidity (50 ± 1)% and were kept on a 12 h light/dark cycle.
They were fed with standard pellet diet from Jiangsu Provincial
Synergistic Engineering Co. Ltd. and water ad libitum. Animals
were made to acclimatize with the new environment for 7 days
before experimentation. Then they were fasted 12 h before each
test. The animal care and use complied with the Provisions and
General Recommendations of the Chinese Experimental Ani-
mals Administration Legislation. The experiments were per-
formed with the approval from the Animal Ethics Committee of
China Pharmaceutical University.
2.4. Evaluation of anti-inﬂammatory property in Wistar
rats
2.4.1. Carrageenan-induced paw oedema
Carrageenan-induced paw oedema was one of the models
used for evaluation of anti-inﬂammatory effect as described by
Winter et al. with some modiﬁcations [7]. The baseline values of
the paw volume were taken at 0 h using a plethysmometer. A
total of 48 rats were divided into six groups, with eight rats in
each group. The drugs were administered in the following
manner:
Group 1 received 4 mL of distilled water as the negative
control;
Group 2 received 10 mg/kg of indomethacin as the positive
control;
Groups 3, 4, 5 received 100 mg/kg, 200 mg/kg and 400 mg/
kg of K-601, respectively;
Group 6 received normal saline.
After 1 h, 0.1 mL of carrageenan (1% in normal saline) was
injected into the subcutaneous tissue of the right hind paws of
each animal and the paw volumes were measured at 1, 2, 3, 4
and 5 h. Oedema was expressed as the mean increase in paw
volume relative to control animals. The percentage inhibition of
oedema was calculated using the following equation:
Inhibition ð%Þ=
ðVt −V0Þcontrol − ðVt −V0Þtreated

ðVt −V0Þcontrol
× 100
where V0 is paw volume at 0 h, Vt is paw volume at 1, 2, 3, 4,
5 h.
Raphael Nammahime Alolga et al./Asian Pac J Trop Biomed 2015; 5(11): 921–927 9232.4.2. Xylene-induced ear oedema
Six groups (n = 8) of the rats were treated as follows:
Groups 1, 2, 3 received 100 mg/kg, 200 mg/kg, and 400 mg/
kg body weight of K-601;
Group 4 received 10 mg/kg of indomethacin;
Group 5 received 4 mg/kg of dexamethasone i.p.;
Group 6 received normal saline as negative control.
After the administration of the drugs for 60 min, each animal
received 20 mL of xylene on the anterior and posterior surfaces
of the right ear. The left ear was considered as normal control.
After another 60 min, the animals were sacriﬁced and both ears
were sampled with a punch (5 mm diameter) and weighed. The
extent of oedema was evaluated by the weight difference be-
tween the right and left ear biopsies of the same animal.
2.5. Evaluation of antipyretic activity
2.5.1. LPS-induced fever in Wistar rats
The animals were randomly divided into six groups (n = 8).
Animals in Groups 1, 2, 3 received 100, 200 and 400 mg/kg
body weight of the drug, K-601 by gavage. In Group 4, each
animal received 10 mg/kg body weight of indomethacin. Ani-
mals in Group 5 received 4 mg/kg body weight of dexametha-
sone via intraperitoneal injection. Animals in Group 6 received
the vehicle, pyrogen-free water. After 30 min the animals in
Group 6 received pyrogen-free sterile normal saline solution
while the other groups were injected intraperitoneally with LPS
(500 mg/kg) dissolved in pyrogen-free sterile normal saline so-
lution. Body temperature (Tb) was taken every h for 5 h after
LPS administration.
These experiments were performed during the light phase of
the circadian cycle. Tb was measured by gently inserting a small
thermoprobe about 4 cm into the rectum until a beep sound heard.
During the temperature measurements, each animal was held
gently and performed at least twice 2 days prior to the experiment
to avoid changes in rectal temperature secondary to handling.
Only animals with stable body temperature and in the range 32.4–
37.0 C were used in the investigation of the inﬂuence of the drug
on the Tb of the animals upon induction of pyrexia with LPS.
2.6. Mechanisms of activity
2.6.1. Test for cytokines (IL-1b, TNF-a) and PGE2
The IL-1b, TNF-a and PGE2 levels in the supernatants were
measured using ELISA kits (Cusabio Biotech., Co. Ltd., Wuhan,
China) according to the manufacturer's instructions. Brieﬂy,
diluted standards or samples were added to 96-well plates pre-
coated with afﬁnity puriﬁed polyclonal antibody speciﬁc rat IL-
1b, TNF-a and PGE2. Into these wells, enzyme-linked poly-
clonal antibodies were added and incubated at 37 C for 60 min,
and washed 5 times. After the addition of the substrate solutions,
their intensities were detected at 450 nm, which were propor-
tional to the productions of IL-1b, TNF-a and PGE2.
2.6.2. Nitric oxide (NO) assay
The amount of nitrite as an indicator of NO production was
measured using Griess reagent. In brief, supernatants from the
plasma of each animal in each model were mixed with same
volume of Griess reagents A & B. After incubation at room
temperature for 10 min in a dark place, the absorbance was
measured at 540 nm using Biotek Synergy 2 spectrophotometer.2.7. Histopathology of the inﬂamed paw of Wistar rats
Biopsies of right hind paws of the rats were collected after
the induction of inﬂammation with carrageenan for 5 h. Tissues
slices were ﬁxed in formalin-acetic acid ﬁxative (100%
formalin & 1% acetic acid) at room temperature, dehydrated,
embedded in parafﬁn and sectioned into 4 mm. Tissue sections
were stained with haematoxylin and eosin and examined with
Olympus IX51, Japan microscope. The tissue slices were
randomly taken from the paws of rats from the following
groups: indomethacin (positive control) group, group that
received the highest dose of K-601 (400 mg/kg body weight),
the model group as well as from rats not given the carrageenan
injection (negative control).
2.8. Statistical analysis
The results were expressed as mean ± SEM. Differences
between control and treatment groups were analyzed using One-
way analysis of variance (ANOVA) with GraphPad Prism 5.0
software as described in Dunnett's test. P < 0.05 was considered
signiﬁcant; P < 0.01 was considered very signiﬁcant while
P < 0.001 was considered highly signiﬁcant.
3. Results
3.1. Identiﬁcation of constituents of K-601
Using a strategy developed in our lab [8], 50 compounds were
tentatively identiﬁed by UPLC-QTOF/MS. The retention times
and MS data of the characterized compounds are summarized in
Table 1.
3.2. Evaluation of anti-inﬂammatory activity in Wistar
rats
3.2.1. Effects on carrageenan-induced paw oedema
The paw size increased steadily until it peaked at 3 h after
injection with carrageenan (seen clearly in the negative control
group). The various doses of K-601 reduced the paw size at the
time points in a dose-dependent manner. The highest dose of
400 mg/kg even proved more effective in reducing inﬂammation
after 5 h than the control drug, indomethacin. This is shown in
Figure 1.
3.2.2. Effects on xylene-induced ear oedema
The effect of the drug K-601 on the reduction of the ear
size of the rats upon induction of oedema with xylene was
investigated. In this model varying doses (100, 200, and
400 mg/kg body weight) of the formulation were given and
their effects were compared to two positive controls (indo-
methacin and dexamethasone) and a negative control. Figure 2
illustrates the outcome in bar chart. The effect of the formu-
lation was dose-dependent, 400 mg/kg body weight giving the
highest level of inhibition (thus with the lowest weight of the
inﬂamed ears). The two positive controls exhibited compara-
ble effects with dexamethasone giving higher inhibition rate.
The inhibition rates compared to the control group gave P-
values as follows: P < 0.05, P < 0.01, P < 0.001 respectively
for 200 mg/kg and 400 mg/kg of K-601 and the positive
controls respectively.
Table 1
Compounds identiﬁed in K-601 in positive and negative ion modes.
No. tR
(min)
ESI
mode
Fragment ions (m/z) Formula Identity Abund.
( × 106)
Peak
abundance
Source
1 4.265 − 169.0134, 125.0246 C7H6O5 Gallic acid
a 16.06 High RP
2 6.174 − 331.0670, 271.0433, 211.0235, 169.0139 C13H16O10 Gallic acid 3-O-b-D-glucopyranoside 2.93 Medium RP
3 11.765 − 389.1051, 345.1085, 183.0641, 165.0548 C16H22O11 Secologanoside 16.70 High LJ
4 17.136 − 353.0871, 191.0540 C16H18O9 Chlorogenic acid
a 4.78 Medium LJ
5 17.360 − 179.0331, 135.0430 C9H8O4 Caffeic acid
a 3.17 Medium LJ
6 22.593 − 353.0869, 191.0533, 179.0316,
173.0424, 161.0187, 135.0421
C16H18O9 4-O-caffeoylquinic acid 22.43 High LJ
7 22.999 − 353.0863, 191.0531, 179.0316, 173.0324 C16H18O9 5-O-caffeoylquinic acid 21.06 High LJ
8 24.536 − 357.1197, 195.0671, 151.0761, 125.0251 C16H22O9 Sweroside 9.72 Medium LJ
9 26.053 − 367.1028, 191.0534 C17H20O9 Caffeoyl–CH2–O-quinic acid 8.36 Medium LJ
10 32.450 − 269.0439, 240.0408, 211.0400 C15H10O5 Aloe-emodin
a 0.21 Low RP
11 33.286 − 609.1475, 301.0325 C27H30O16 Rutin
a 0.53 Low SC
12 33.455 − 445.0756, 283.0241, 239.0326, C21H18O11 Rhein-8-O-b-D-glucopyranoside 0.04 Low RP
13 33.658 − 447.0897, 285.0396 C21H20O11 Luteolin-7-O-b-D-glucoside 0.75 Low RP
14 33.692 − 463.0895, 301.0340, 271.0291 C21H20O12 Hyperoside 0.42 Low LJ
15 33.861 − 461.0737, 285.0339 C21H18O12 Scutellarin 0.47 Low SB
16 33.937 − 593.1519, 447.0962, 285.0401 C27H30O15 Lonicerin
a 0.52 Low LJ
17 34.756 − 515.1189, 353.0873, 191.0551, 179.0346 C25H24O12 1,5-O-dicaffeoylquinic acid or
4,5-O-dicaffeoylquinic acid or
1,4-O-dicaffeoylquinic acid
0.05 Low LJ
18 36.809 − 269.0476, 167.0507 C15H10O5 Baicalein
a 0.12 Low SB
19 37.817 − 269.0456, 240.0408, 211.0400, 167.0518 C15H10O5 Emodin
a 12.33 High RP
20 38.152 − 269.0452, 225.0539, 197.0564, 183.0448 C15H10O5 Apeginin 0.24 Low LJ
21 38.701 − 253.0488, 225.0556 C15H10O4 Chrysophanol 0.22 Low RP
22 39.326 − 253.0504, 225.0557 C15H10O4 Chrysin 0.31 Low RP
23 39.410 − 431.0987, 395.1032, 311.0588, 269.0468 C21H20O10 Aloe-emodin-8-O-glucoside 0.40 Low RP
24 40.027 − 459.0952, 283.0612, 268.0376 C22H20O11 Wogonoside
a 16.97 High SB
25 40.263 − 283.0605, 268.0363, 240.0372 C16H12O5 Physcion 0.72 Low RP
26 43.895 − 269.0463, 241.0521, 225.0543 C15H10O5 Norwogonin 0.26 Low SB
27 45.416 − 313.7373, 229.2099, 211.1348, 171.1012 C18H34O5 Sanleng acid 2.90 Medium RP
28 47.544 − 297.0409, 253.0501, 225.0517 C16H10O6 6-Methyl-rhein 0.17 Low RP
29 52.055 − 283.0260, 239.0343, 211.0411, 183.0413 C15H8O6 Rhein
a 0.28 Low RP
30 4.076 + 180.1286, 121.0535 C11H18NO Candicine 4.02 Medium PC
31 20.496 + 314.1716, 269.1167, 237.0903,
192.1009, 143.0486
C19H23NO3 Lotusine 24.34 High PC
32 22.430 + 342.1687, 192.1007 C20H24NO4 Phellodendrine
a 25.40 High SB
33 23.461 + 344.1854, 299.1283, 207.0766,
175.0748, 137.0590
C20H26NO4 Tembetarine 20.21 High PC
34 23.498 + 342.1730, 297.1121, 265.0859 C20H23NO4 Magnoﬂorine
a 25.39 High PC
35 24.120 + 342.1684, 297.1102, 265.0852 C20H23NO4 Tetrahydrojatrorrhizine 25.32 High PC
36 28.613 + 356.1853, 311.1271, 279.1016 C21H25NO4 Menisperine 22.31 High PC
37 30.260 + 312.1591, 297.1361, 267.1191, 252.1016 C19H21NO3 Veticuline 0.32 Low PC
38 31.966 + 356.1854, 192.1017 C21H25NO4 Tetrahydropalmatine 24.19 High PC
39 31.975 + 356.1855, 297.0821, 192.1017,
177.0780, 148.0752
C21H26NO4 N-Methyltetrahydrocolumbamine 23.19 High PC
40 35.193 + 338.1377, 322.1072, 308.0908,
294.1118, 280.0951
C20H20NO4 Jatrorrhizine
a 2.03 Medium PC
41 37.544 + 352.1534, 336.1228, 322.1074,
308.1277, 294.1121
C21H22NO4 Palmatine
a 25.38 High PC
42 37.722 + 336.1233, 334.1071, 306.0764, 292.0968 C20H18NO4 Berberine
a 23.26 High PC
43 37.783 + 445.0772, 271.0608 C21H18O11 Baicalin
a 24.40 High SB
44 38.119 + 320.0911, 292.0962 C20H18NO4 Epiberberine 0.06 Low PC
45 38.600 + 263.0820 C16H10N2O2 Indigotin 0.25 Low II
46 42.955 + 437.3389, 409.3480, 366.0660 C26H30O7 Obacunone 0.12 Low PC
47 44.121 + 329.2210, 316.0589, 301.0377,
287.0624, 273.0374
C17H14O7 Iristectorigenin A or
Iristectorigenin B
1.73 Medium LJ
48 44.121 + 329.2210, 316.0589, 301.0377,
287.0624, 273.0374
C17H14O7 Iristectorigenin A or
Iristectorigenin B
1.73 Medium LJ
49 50.202 + 453.1858, 425.1962, 367.1909 C26H30O8 Obaculactone 2.33 Medium PC
50 51.520 + 285.0760, 270.0522 C16H12O5 Wogonin
a 2.80 Medium SB
a Conﬁrmed with reference compounds. The relative abundance of the compounds measured by the peak height in the extracted ion chromatogram
>10.00 × 106, deﬁned as major constituent, thus high level; (1.00 – 10.00) × 106, deﬁned as minor constituent, meaning moderate level; <1.00 × 106
deﬁned as trace constituent, hence present in low levels. PC: P. chinense; LJ: L. japonica; II: I. indigotica; SC: S. baicalensis; RP: Rheum palmatum.
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Figure 1. The effects of varying doses of K-601 and indomethacin on the
paw size of rats with time.
The asterisk denotes the signiﬁcance levels in comparison with the negative
control: *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 2. The effects of varying doses of K-601, indomethacin and
dexamethasone on the xylene-induced ear oedema of rats.
1: Control; 2: 100 mg/kg; 3: 200 mg/kg; 4: 400 mg/kg; 5: Indomethacin; 6:
Dexamethasone. The asterisks indicate the levels of signiﬁcance in com-
parison with the control: *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 3. The effects of different doses of K-601, indomethacin and
dexamethasone on LPS-induced fever with time.
The asterisks denote the levels of signiﬁcance in comparison with the
negative control group: *P < 0.05, **P < 0.01.
Figure 4. Histological changes in oedema paws 5 h after injection of carragee
Paws were cut 5 h after injection of carrageenan and subjected to histochemic
group; C: 400 mg/kg body weight of K-601; D: indomethacin as positive cont
Raphael Nammahime Alolga et al./Asian Pac J Trop Biomed 2015; 5(11): 921–927 9253.3. Evaluation of antipyretic activity in Wistar rats
The LPS-induced fever peaked 2 h after injection. The
reduction in body temperature was also dose-dependent using K-
601 with 400 mg/kg body weight giving the maximum effect.
This high dose however was not as effective as the positive
controls, indomethacin and dexamethasone. Dexamethasone
(4 mg/kg) proved a little more effective than indomethacin at
reducing the body temperature 5 h after experimentation prob-
ably due to the fact that it was given i.p. as shown in Figure 3.
3.4. Histopathological analysis of rat paw
The histopathological results shown in Figure 4 showed no
cellular inﬁltration or oedema in the control group (Figure 4A).
In contrast, polymorphonuclear inﬁltration and swelling fol-
lowed carrageenan injection (Figure 4B). After treatment with
400 mg/kg of K-601, there were signiﬁcant reductions in the
polymorphonuclear inﬁltrations and oedema as shown in
Figure 4C which compared with the standard control drug of
indomethacin (Figure 4D).nan.
al staining of paw tissues. A: Saline control group; B: Carrageenan model
rol drug. Magniﬁcation ×20.
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Tentative identiﬁcation of compounds could be an arduous
task especially when reference compounds are not available.
With reference compounds, similar compounds could be iden-
tiﬁed based on their retentions times, fragmentation patterns and
other data in literature. In the absence of reference compounds, a
lot of strategies have been employed for tentative identiﬁcation
and structural conﬁrmation. The strategy employed in the
identiﬁcation was a method called diagnostic ion ﬁltering
strategy [8]. Brieﬂy the diagnostic ions corresponding to a
mother skeleton obtained from reference compounds are used
to screen the same type of compounds. Then, the molecular
ions of screened peaks are calculated using both negative and
positive ion modes. Next, the accurate molecular formula of
each peak obtained was applied to screening for a hit against
various chemical databases. A most possible structure that
contains such a substructure and substituent groups can be
determined from these candidates by comparison of
characteristic product ions and fragmentation pathways.
The outcome of the identiﬁcation of the constituents of the
formulation K-601 revealed it contains a variety of compounds
ranging from ﬂavonoids, isoﬂavonoids, to alkaloids, etc. In total,
50 compounds were tentatively identiﬁed in both the positive
and negative ion modes. The identiﬁcation of the chemical
make-up of this formulation proved useful in explaining its
possible mechanisms of actions.
Carrageenan-induced paw oedema is a good, reliable and
repeatable in vivo experimental model employed to investigate
anti-inﬂammatory agents. Following carrageenan injection, the
development of oedema is believed to be biphasic [9,10] that
eventually leads to signs of inﬂammation such as oedema,
hyperalgesia and erythema. The early phase involves the
release of inﬂammatory mediators such as histamine, serotonin
and bradykinins while the late phase is associated with the
release of prostaglandins [10]. It is also known that platelet
activating factor and arachidonic acid metabolites play a vital
role in the phase 1 of inﬂammation [11]. The resultant effect
leads to increased vascular permeability, which enhances the
inﬁltration of neutrophils and the accumulation of plasma ﬂuid
into the interstitial space which leads to oedema [9]. The
results of this study reveals that inﬂammation was inhibited at
both phases though the latter phase showed more signiﬁcance.
It was also revealed that the levels of inhibition of
inﬂammation were dose-dependent. The dose of 400 mg/kg
body weight gave better results in terms of the reduction of
inﬂammation compared with the control drug of indomethacin at
times 3 h, 4 h and 5 h.
The xylene-induced ear oedema is another inﬂammation
model that was used. Xylene, a well-known inﬂammatory
agent, provokes acute inﬂammatory response in the ear of the
rat leading to serious oedematous changes of skin when
applied to the ear. The acute inﬂammatory response, severe
vasodilation and oedematous changes of the skin is partially
associated with phospholipase A2 as reported by Luber-Narod
et al. [12], Kim et al. [13] and Wang et al. [14]. The formulation
K-601 also reduced inﬂammation in the ears of the rats in a
dose-dependent manner, with 400 mg/kg giving the highest
outcome.
Fever is commonly studied in the laboratory by injecting
animals with bacterial LPS or mediators of its action such as pro-
inﬂammatory cytokines, IL-1b, IL-6 and TNF-a. It has beenreported that LPS-induced fever in rats is polyphasic with
different underlying mechanisms [15]. The response of the
animals to the fever depends on the serotype and dose of LPS,
injection route and stress, ambient temperature, animal strain,
gender differences [16–18]. Tb of the animals increased 1 h
after injection of LPS and peaked at 2 h and 5 h. Though the
underlying process of fever initiation and sustenance are
multiple, varied and complex, it is believed that LPS causes
fever by stimulating peripheral macrophages to synthesize and
release pyrogenic cytokines such as IL-1b, TNF-a and IL-6.
These cytokines are transported to the thermoregulatory centre
of the anterior hypothalamus and consequently stimulate the
production of PGE2. PGE2 ultimately leads to the elevation of
temperature, hence fever. PGE2 is a major mediator of fever and
present in all phases of the polyphasic LPS-induced fever [16,19].
NO is also found to be a part of several systems that are involved
in Tb regulation and NO acting peripherally has been found to
be pyretic [20].
In the investigation of K-601 as a potential antipyretic agent,
it was found that it possesses the ability to reduce fever but also
in a dose-dependent manner as shown in Figure 3. Its effect
however even with the high dose of 400 mg/kg body weight
though signiﬁcant after 5 h could not compare with the positive
controls of dexamethasone and indomethacin.
The possible mechanisms of actions of this formulation could
be due to the inhibition of NO production, inhibition of cyto-
kines release as well as the inhibition of PGE2 release in
inﬂammation and at the various phases of LPS-induced pyrexia.
The probable reasons for the activity of K-601 as an anti-
inﬂammatory and antipyretic agent could be traced back to its
composition. As earlier mentioned, this formulation contains
ﬂavonoids, isoﬂavonoids, alkaloids, etc. Flavonoids have been
found to have anti-oxidative and free radical scavenging activ-
ities. They could regulate cellular activities of inﬂammation-
related cells, thus, mast cells, macrophages, lymphocytes and
neutrophils. Certain ﬂavonoids modulate the enzyme activities
of arachidonic acid, metabolizing enzymes such as phospholi-
pase A2, cyclooxygenase, lipoxygenase and the NO producing
enzyme, NO synthase. Therefore inhibition of these enzymes by
ﬂavonoids leads to reduced production of arachidonic acid,
prostaglandins, leukotrienes and NO, which are crucial media-
tors of inﬂammation [21]. Another anti-inﬂammatory property of
ﬂavonoids is their ability to inhibit nuclear factor kappa B
transcription activation [22,23].
Alkaloids have also been found to be good anti-inﬂammatory
agents. For instance indole alkaloids from the roots of
I. indigotica has been found to have inhibitory effects on NO
production [24], alkaloidal fraction from Alstonia scholaris
including picrinine, vallesamine and scholaricine was also
found to inhibit NO and prostaglandin, PGE2 production.
Various alkaloids therefore exhibit their activities via different
mechanisms.
The histopathological analyses also showed the extent to
which K-601 could ameliorate inﬂammation. K-601 (400 mg/kg
body weight) proved effective in preventing polymorphonuclear
inﬁltration into the site of inﬂammation (paw) which compared
favourably with the control drug, indomethacin.
Herbal formulations have been found to contain bioactive
compounds that usually act in synergy to give the desired
pharmacological effects. Thus the effects of the formulation, K-
601 could be due to different compounds acting in consonance
and not necessarily one speciﬁc compound.
Raphael Nammahime Alolga et al./Asian Pac J Trop Biomed 2015; 5(11): 921–927 927Our ﬁndings however, are in agreement with other re-
searchers who worked on the individual components of this
formulation. L. japonica is commonly used for the treatment of
sores, carbuncles, furuncles, swelling and infections caused by
exopathogenic wind-heat or epidemic febrile diseases at the
early stage of life. It is also found to have hepatoprotective,
cytoprotective, antimicrobial, antioxidative, antiviral and anti-
inﬂammatory effects [25]. I. indigotica has been found useful
in preventing and treating inﬂuenza, tonsillitis, and malignant
infectious diseases [26] especially severe acute respiratory
syndrome and H1N1-inﬂuenza [27] because of its anti-viral,
anti-bacterial, anti-inﬂammatory, anti-tumour, and immune
regulatory functions. P. chinense is a well-known oriental folk
medicine as an effective anti-inﬂammatory, antiphlogistic and
antipyretic agent in clinical usage [28]. S. baicalensis is
traditionally used for the treatment of inﬂammation, asthma as
well as throat disorders, e.g. cough, tonsillitis and pharyngitis
[29]. The combined effects of all these components were thus
investigated.
In conclusion, the formulation K-601 was found to possess
anti-inﬂammatory and antipyretic activities. It was found to
inhibit the production of NO, the release of cytokines (IL-1b,
TNF-a) and PGE2. The outcome of this research provides a solid
foundation for further pharmacological studies on this unique
formulation which is actually ongoing.
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